Phenotype, Localization, and Mechanism of Suppression of CD4(+)CD25(+) Human Thymocytes
Overview
General Medicine
Authors
Affiliations
Phenotypic markers, localization, functional activities, and mechanisms of action in vitro of CD4(+)CD25(+) T cells, purified from postnatal human thymuses, were investigated. These cells showed poor or no proliferation in mixed lymphocyte culture (MLC), and suppressed in a dose-dependent fashion the proliferative response to allogeneic stimulation of CD4(+)CD25(-) thymocytes. Virtually all CD4(+)CD25(+) thymocytes constitutively expressed cytoplasmic T lymphocyte antigen (CTLA)-4, surface tumor necrosis factor type 2 receptor (TNFR2), and CCR8. They prevalently localized to perivascular areas of fibrous septa and responded to the chemoattractant activity of CCL1/I-309, which was found to be produced by either thymic medullary macrophages or fibrous septa epithelial cells. After polyclonal activation, CD4(+)CD25(+) thymocytes did not produce the cytokines interleukin (IL)-2, IL-4, IL-5, IL-13, interferon gamma, and only a very few produced IL-10, but all they expressed on their surface CTLA-4 and the majority of them also transforming growth factor (TGF)-beta1. The suppressive activity of these cells was contact dependent and associated with the lack of IL-2 receptor (IL-2R) alpha-chain (CD25) expression in target cells. Such a suppressive activity was partially inhibited by either anti-CTLA-4 or anti-TGF-beta1, and was completely blocked by a mixture of these monoclonal antibodies, which were also able to restore in target T cells the expression of IL-2R alpha-chain and, therefore, their responsiveness to IL-2. These data demonstrate that CD4(+)CD25(+) human thymocytes represent a population of regulatory cells that migrate in response to the chemokine CCL1/I-309 and exert their suppressive function via the inhibition of IL-2R alpha-chain in target T cells, induced by the combined activity of CTLA-4 and membrane TGF-beta1.
Melatonin, an Antitumor Necrosis Factor Therapy.
Alvarez-Lopez A, Cruz-Chamorro I, Lardone P, Bejarano I, Aspiazu-Hinostroza K, Ponce-Espana E J Pineal Res. 2024; 77(1):e70025.
PMID: 39740227 PMC: 11685806. DOI: 10.1111/jpi.70025.
Defining Human Regulatory T Cells beyond FOXP3: The Need to Combine Phenotype with Function.
Gootjes C, Zwaginga J, Roep B, Nikolic T Cells. 2024; 13(11.
PMID: 38891073 PMC: 11172350. DOI: 10.3390/cells13110941.
The TNFα/TNFR2 axis mediates natural killer cell proliferation by promoting aerobic glycolysis.
Khan A, Ali A, Marr B, Jo D, Ahmadvand S, Fong-McMaster C Cell Mol Immunol. 2023; 20(10):1140-1155.
PMID: 37553427 PMC: 10541863. DOI: 10.1038/s41423-023-01071-4.
Abdeladhim M, Karnell J, Rieder S Front Immunol. 2023; 13:1033705.
PMID: 36591244 PMC: 9799097. DOI: 10.3389/fimmu.2022.1033705.
CD8 T regulatory cells in lupus.
Singh R, S Bischoff D, Hahn B Rheumatol Immunol Res. 2022; 2(3):147-156.
PMID: 35880241 PMC: 9242525. DOI: 10.2478/rir-2021-0021.